Multimodality imaging of tumor and bone response in a mouse model of bony metastasis

Translational Oncology

Volumn 5, Issue 6, 2012, Pages 415-421

  Hoff, Benjamin A ^a   Chughtai, Komal ^a   Jeon, Yong Hyun ^a   Kozloff, Kenneth ^a   Galbán, Stefanie ^b   Rehemtulla, Alnawaz ^b   Ross, Brian D ^a   Galbán, Craig J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CATK 680 FAST; DOCETAXEL; OSTEOSENSE 800; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MASS; BONE METASTASIS; CELL CULTURE MONITORING; CONTROLLED STUDY; DIFFUSION COEFFICIENT; FEMALE; FLUORESCENCE IMAGING; IMAGING; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR IMAGING; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SEVERE COMBINED IMMUNODEFICIENCY; TISSUE REACTION; TUMOR CELL; TUMOR VOLUME;

EID: 84871680913     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12298     Document Type: Article

References (32)

1. Coleman RE (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27, 165-176.
2. Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593.
3. Tkaczuk KH (2009). Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 31(pt 2), 2273-2289.
4. Korpal M, Yan J, Lu X, Xu S, Lerit DA, and Kang Y (2009). Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 15, 960-966.
5. Casimiro S, Guise TA, and Chirgwin J (2009). The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310, 71-81.
6. Guise TA (2002). The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2, 570-572.
7. Joyce JA and Pollard JW (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252.
8. Ooi LL, Zheng Y, Stalgis-Bilinski K, and Dunstan CR (2011). The bone remodeling environment is a factor in breast cancer bone metastasis. Bone 48, 66-70.
9. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, and Dunstan CR (2007). Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40, 471-478.
10. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, and Guise TA (2009). Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 4, e6896.
11. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, and Ueno NT (2010). Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7, 641-651.
12. Rose AA and Siegel PM (2010). Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6, 55-74.
13. Galbán S, Jeon YH, Sharkey LM, Hoff BA, Galbán CJ, Ross BD, and Rehemtulla A (2012). A genetically engineered mouse for imaging of apoptosis in a tissue specific manner. In Proceedings of the 103rd AACR Annual Meeting, 2012 March 31-April 4. Chicago, IL. Poster session presented at: AACR 2012.
14. Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL, Rehemtulla A, and Ross BD (2004). Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 17, 249-259.
15. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92, 2029-2036.
16. Galbán CJ, Bhojani MS, Lee KC, Meyer CR, Van Dort ME, Kuszpit KK, Koeppe RA, Ranga R, Moffat BA, Johnson TD, et al. (2010). Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res 16, 1542-1552.
17. Hamstra DA, Rehemtulla A, and Ross BD (2007). Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25, 4104-4109.
18. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, et al. (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2, 581-587.
19. Hoff BA, Chenevert TL, Bhojani MS, Kwee TC, Rehemtulla A, Le Bihan D, Ross BD, and Galbán CJ (2010). Assessment of multiexponential diffusion features as MRI cancer therapy response metrics. Magn Reson Med 64, 1499-1509.
20. Bauerle T, Bartling S, Berger M, Schmitt-Graff A, Hilbig H, Kauczor HU, Delorme S, and Kiessling F (2010). Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol 73, 280-287.
21. Walker-Samuel S, Leach MO, and Collins DJ (2006). Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 51, 3593-3602.
22. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, et al. (2007). Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25, 1-13.
23. Hoff BA, Bhojani MS, Rudge J, Chenevert TL, Meyer CR, Galbán S, Johnson TD, Leopold JS, Rehemtulla A, Ross BD, et al. (2011). DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. NMR Biomed 25, 935-942.
24. Tomita A, Kasaoka T, Inui T, Toyoshima M, Nishiyama H, Saiki H, Iguchi H, and Nakajima M (2008). Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis. Clin Exp Metastasis 25, 437-444.
25. Xie BW, Mol IM, Keereweer S, van Beek ER, Que I, Snoeks TJ, Chan A, Kaijzel EL, and Lowik CW (2012). Dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model. PLoS One 7, e31875.
26. Bhojani MS, Nyati MK, Zhao L, Normolle DP, Ross BD, Lawrence TS, and Rehemtulla A (2011). Molecular imaging of Akt enables early prediction of response to molecular targeted therapy. Transl Oncol 4, 122-125.
27. Coppola JM, Ross BD, and Rehemtulla A (2008). Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res 14, 2492-2501.
28. Nyati S, Schinske K, Ray D, Nyati M, Ross BD, and Rehemtulla A (2011). Molecular imaging of TGFβ-induced Smad2/3 phosphorylation reveals a role for receptor tyrosine kinases in modulating TGFβ signaling. Clin Cancer Res 17, 7424-7439.
29. Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, Coxon A, Galbán CJ, Ross BD, and Rehemtulla A (2011). Molecular imaging of c-Met tyrosine kinase activity. Anal Biochem 412, 1-8.
30. Galbán CJ, Galbán S, Van Dort ME, Luker GD, Bhojani MS, Rehemtulla A, and Ross BD (2010). Applications of molecular imaging. Prog Mol Biol Transl Sci 95, 237-298.
31. Khan AP, Contessa JN, Nyati MK, Ross BD, and Rehemtulla A (2011). Molecular imaging of epidermal growth factor receptor kinase activity. Anal Biochem 417, 57-64.
32. Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD, and Rehemtulla A (2007). Molecular imaging of Akt kinase activity. Nat Med 13, 1114-1119.